Literature DB >> 33804419

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.

Florencia Veigas1, Yamil D Mahmoud1, Joaquin Merlo1, Adriana Rinflerch2, Gabriel Adrian Rabinovich3,4, María Romina Girotti1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors usually diagnosed at an advanced stage and characterized by a poor prognosis. The main risk factors associated with its development include tobacco and alcohol consumption and Human Papillomavirus (HPV) infections. The immune system has a significant role in the oncogenesis and evolution of this cancer type. Notably, the immunosuppressive tumor microenvironment triggers immune escape through several mechanisms. The improved understanding of the antitumor immune response in solid tumors and the role of the immune checkpoint molecules and other immune regulators have led to the development of novel therapeutic strategies that revolutionized the clinical management of HNSCC. However, the limited overall response rate to immunotherapy urges identifying predictive biomarkers of response and resistance to treatment. Here, we review the role of the immune system and immune checkpoint pathways in HNSCC, the most relevant clinical findings linked to immunotherapeutic strategies and predictive biomarkers of response and future treatment perspectives.

Entities:  

Keywords:  head and neck cancer; immune checkpoint; immune infiltrate; immunotherapy

Year:  2021        PMID: 33804419      PMCID: PMC7957692          DOI: 10.3390/cancers13051018

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  130 in total

Review 1.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

2.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

Authors:  Takeshi Ogino; Hiroshi Shigyo; Hideyuki Ishii; Akihiro Katayama; Naoyuki Miyokawa; Yasuaki Harabuchi; Soldano Ferrone
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

3.  Interleukin-6 predicts recurrence and survival among head and neck cancer patients.

Authors:  Sonia A Duffy; Jeremy M G Taylor; Jeffrey E Terrell; Mozaffarul Islam; Yun Li; Karen E Fowler; Gregory T Wolf; Theodoros N Teknos
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

Review 4.  Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures.

Authors:  Scott E Kern
Journal:  Cancer Res       Date:  2012-11-19       Impact factor: 12.701

5.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

Review 7.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.

Authors:  Emma J de Ruiter; Marc L Ooft; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2017-08-09       Impact factor: 8.110

8.  Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.

Authors:  Yi Zheng; Tingting Wang; Xiaoxuan Tu; Yun Huang; Hangyu Zhang; Di Tan; Weiqin Jiang; Shunfeng Cai; Peng Zhao; Ruixue Song; Peilu Li; Nan Qin; Weijia Fang
Journal:  J Immunother Cancer       Date:  2019-07-23       Impact factor: 13.751

9.  The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.

Authors:  Andrew A Davis; Vaibhav G Patel
Journal:  J Immunother Cancer       Date:  2019-10-26       Impact factor: 13.751

10.  Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.

Authors:  Yang Gao; Naoe Taira Nihira; Xia Bu; Chen Chu; Jinfang Zhang; Aleksandra Kolodziejczyk; Yizeng Fan; Ngai Ting Chan; Leina Ma; Jing Liu; Dong Wang; Xiaoming Dai; Huadong Liu; Masaya Ono; Akira Nakanishi; Hiroyuki Inuzuka; Brian J North; Yu-Han Huang; Samanta Sharma; Yan Geng; Wei Xu; X Shirley Liu; Lei Li; Yoshio Miki; Piotr Sicinski; Gordon J Freeman; Wenyi Wei
Journal:  Nat Cell Biol       Date:  2020-08-24       Impact factor: 28.213

View more
  5 in total

1.  Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.

Authors:  Yuming Chen
Journal:  Dis Markers       Date:  2022-06-15       Impact factor: 3.464

Review 2.  Current trends of targeted therapy for oral squamous cell carcinoma.

Authors:  Hongjiao Li; Yao Zhang; Mengmeng Xu; Deqin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-02       Impact factor: 4.322

3.  Systemic Analysis on the Features of Immune Microenvironment Related to Prognostic Signature in Head and Neck Squamous Cell Carcinoma.

Authors:  Kaixin Su; Zekun Zhou; Qiao Yi; Junjie Liu; Tiao Luo; Xinyan Cui; Haixia Zhang
Journal:  Front Genet       Date:  2022-05-11       Impact factor: 4.772

4.  Implications of Human Antimicrobial Peptide Defensin Beta-1 in Clinical Oral Squamous Cell Carcinoma Patients via an Integrated Bioinformatics Approach.

Authors:  Simin Li; Hu Li; Yuzhen Xu; Wanchen Ning; Shaonan Hu; Shanzun Wei; Hongning Song; Jianghe Sun; Dirk Ziebolz; Gerhard Schmalz; Xianda Hu; Min Liu
Journal:  Comput Math Methods Med       Date:  2022-02-18       Impact factor: 2.238

5.  Predictive Role of NEK6 in Prognosis and Immune Infiltration in Head and Neck Squamous Cell Carcinoma.

Authors:  Zhi-Min Yang; Bing Liao; Si-Si Yang; Tong Su; Jing Zhang; Wei-Ming Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.